China's Three-Healthcare Coordination Policy: Medical Device Implications — UDI, VBP & Clinical Urgent Import (2025)

China's healthcare system is undergoing one of its most significant structural realignments in decades. The policy concept of 三医协同 — coordinated reform across medical treatment (医疗), medical insurance (医保), and pharmaceuticals and medical devices (医药/医械) — has shifted from a guiding principle into a concrete operational mandate. The anchor document, 国办发[2024]53号, issued by the State Council Office, assigns specific responsibilities to NMPA, the National Healthcare Security Administration (NHSA), the National Health Commission (NHC), the Ministry of Industry and Information Technology (MIIT), and the National Development and Reform Commission (NDRC).

For medical device manufacturers — especially foreign companies navigating the China market — understanding the three-healthcare coordination framework is no longer optional. It determines how quickly innovative products reach the market, whether they qualify for medical insurance reimbursement, how UDI compliance interacts with procurement and distribution systems, and what quality obligations accompany volume-based procurement contracts. This article unpacks each dimension.

The Policy Architecture: What 国办发[2024]53号 Actually Requires

The 53号 document assigns three categories of tasks relevant to medical devices:

Clinical Urgent Import: A New Pathway for Unregistered Devices

One of the most practically significant new mechanisms is the clinical urgent import pathway formalized in 2024年第97号公告 (NMPA Announcement No. 97, 2024). This policy creates a legitimate route for Level-3A hospitals to obtain and use Class II or III medical devices that are approved overseas but not yet registered in China — without waiting for a full NMPA registration.

Scope and Eligibility

The clinical urgent import pathway applies to:

• Class II and Class III medical devices only (not Class I)
• Devices already approved in their country of origin
• Devices with no equivalent registered product in China (the "same product" standard uses the same broad comparator definition as NMPA registration: same basic principles, structure, materials, manufacturing, performance requirements, safety evaluation, applicable standards, and intended use)
• Devices needed for clinical urgency: treatment of life-threatening conditions for which no effective domestic alternative exists
• Large capital medical equipment requiring configuration licensing is excluded

Hospital Eligibility Requirements

The applying hospital must be a Level-3A (三级甲等) hospital and demonstrate:

• Proven capability in treating the relevant complex/critical condition
• A high-level specialist team appropriate to the indication
• Senior expert physicians and a supporting clinical team
• Quality control capability and adverse event monitoring and response infrastructure

Application and Approval Process

Emergency Use: A Separate Track for Public Health Crises

Distinct from clinical urgent import is the emergency use pathway (2023年第150号), which applies during major public health emergencies. Under emergency use, NMPA — on recommendation from NHC and CDC — can authorize specific products for emergency deployment without full registration. The emergency use list is public. This pathway is not routinely accessible and is reserved for genuine public health crisis situations.

UDI: The Digital Spine of Three-Healthcare Coordination

China's Unique Device Identification (UDI) system is, in the three-healthcare coordination framework, more than a traceability tool — it is the information infrastructure that enables "one code connection" (一码联通) across the production, distribution, and clinical use chain, breaking down information silos between NMPA, NHSA, hospitals, and distributors.

Structure and Implementation Phases

China's UDI follows the IMDRF framework (which succeeded the GHTF's 2011 UDI System Guidance): each device carries a Device Identifier (DI — product-level identifier) combined with a Production Identifier (PI — lot/serial/date information). Together: UDI = DI + PI.

Implementation has proceeded in three phases:

• Phase 1: All Class III medical devices (highest priority, implemented first)
• Phase 2 & 3: 15,103 specified Class II medical device product lines

China's UDI database (国家医疗器械唯一标识数据库) is open for external sharing — manufacturers, distributors, hospitals, and insurance systems can access it. This shared data layer enables NMPA traceability, adverse event signal detection, procurement reconciliation, and hospital inventory management from a single source of truth.

Why UDI Compliance Matters Beyond Traceability

The practical stakes of UDI compliance in China extend well beyond regulatory obligation:

• Medical insurance coding linkage: NHSA is mapping UDI device identifiers to medical insurance product codes (医保编码). Devices without a UDI in the NMPA database cannot be efficiently processed for insurance reimbursement or included in national procurement tenders.
• Volume-based procurement eligibility: VBP tenders increasingly require UDI information for product listing and post-award quality tracking. NMPA uses UDI-linked adverse event data to monitor VBP-selected products.
• Hospital systems integration: Major hospital information systems (HIS) and surgical instrument tracking systems are incorporating UDI scanning. Devices without UDI barcodes create friction in hospital procurement and inventory workflows.
• Recall and field safety action efficiency: UDI-enabled traceability allows targeted lot-level recalls rather than broad product-level withdrawal — a significant patient safety and commercial benefit for manufacturers.

NMPA and NHC established a joint UDI pilot coordination working group to oversee the system's expansion and ensure cross-departmental integration.

Medical Insurance Coding: Solving the "Same Name, Different Product" Problem

One of the most chronic administrative challenges in China's medical device ecosystem has been the mismatch between NMPA product naming conventions and NHSA insurance code nomenclature. Manufacturers have historically had significant naming freedom, leading to a market with "same-name different products" and "different-name same products" — making accurate insurance identification, procurement matching, and cost control extremely difficult.

The three-healthcare coordination framework is directly targeting this problem through systematic UDI-to-insurance-code mapping research (医疗器械通用名称与医保通用名映射关系研究). The goal: once a device has an NMPA registration number and UDI, it can be precisely matched to an NHSA insurance code — enabling accurate reimbursement categorization, VBP inclusion assessment, and hospital formulary management.

Medical Insurance Equipment Coding Structure

For medical imaging equipment (a category under active harmonization), NHSA's proposed code format is a 13-digit structure: a 2-letter prefix "CS" (medical device marker), followed by a 6-digit classification code (first 2 digits: functional category; middle 2 digits: technical principle; last 2 digits: intended use/product name), followed by a 5-digit company code derived from the NMPA registration certificate.

This coding architecture is designed to enable direct linkage between the NMPA product name, the UDI device identifier, and the NHSA insurance code — the "triple mapping" that makes true three-healthcare coordination technically feasible.

Volume-Based Procurement (VBP): NMPA's Role in Quality Oversight

China's national volume-based procurement (带量采购/集采) program has swept through medical device categories including coronary stents, orthopedic implants (joints, spine, trauma), intraocular lenses, and intravascular catheters — driving dramatic price reductions. NMPA's explicit role within VBP is quality assurance for selected products, not price negotiation.

NMPA's Six VBP Oversight Responsibilities

Following the 2021 expansion of VBP to orthopedic categories, NMPA formalized its VBP quality management responsibilities into six tasks:

1. Fully enforce manufacturer quality system accountability (主体责任)
2. Strengthen supervisory inspections of VBP-selected manufacturers
3. Conduct distribution and hospital-use inspections
4. Perform systematic quality sampling and testing of selected products
5. Continuously monitor adverse event data for selected products
6. Strictly investigate and penalize regulatory violations

The trigger for this formalization was an NMPA leadership-attended quality safety meeting specifically for coronary stent VBP selection — reflecting the highest political visibility for product quality when prices are compressed through government procurement.

VBP and Innovative Devices: Protected Market Space

The three-healthcare coordination policy explicitly acknowledges a tension between price compression through VBP and the need to preserve market incentives for medical device innovation. The resolution is straightforward: innovative devices where clinical use patterns are not yet established and volumes are difficult to estimate are explicitly excluded from mandatory VBP participation.

NHSA policy reserves a portion of market volume outside VBP specifically to give newly approved innovative devices space to develop their clinical evidence base, build hospital relationships, and demonstrate real-world value — before potentially facing procurement competition in future tender cycles. This protected space is a key consideration in market entry strategies for foreign innovative device companies.

Fast-Track Medical Insurance Code Assignment for New Registrations

In a practical streamlining measure, NMPA and NHSA have established a fast-track window: manufacturers that have received an NMPA registration certificate can submit the registration certificate, product IFU, and product photographs directly to NHSA's "Medical Insurance Information Business Code Standard Database Dynamic Maintenance" portal to accelerate insurance code assignment. NMPA has committed to prioritizing the speed of code assignment for newly registered devices through this portal.

LDT Pilot: Where Medical Devices Meet In-Hospital Innovation

The LDT (laboratory-developed test) pilot program — enabled by Article 53 of the 2021 Medical Device Regulations — sits at the intersection of the three-healthcare coordination framework's commitment to clinical innovation and regulatory modernization. Under the pilot, qualified medical institutions can self-develop IVDs for in-house clinical use, under physician supervision, without a standalone NMPA registration.

The policy logic: China has world-class clinical research institutions capable of developing novel diagnostic tests that serve genuine unmet clinical needs — particularly for rare diseases and specialized oncology applications — faster than the commercial registration pathway allows. The LDT framework channels this clinical innovation within a regulated structure rather than allowing unregulated in-house testing to proliferate.

Beijing's 2025 innovation support measures accelerate the pilot by setting concrete institutional filing targets and explicitly prioritizing rare disease diagnostic LDTs. Shanghai's pilot scheme provides the most detailed operational framework currently available.

Spring Rain Action: Clinical-to-Commercial Innovation Pipeline

The "Spring Rain Action" (春雨行动) is an NMPA-led initiative that adds a forward-looking dimension to the three-healthcare coordination framework. Rather than only managing products through the existing regulatory pipeline, Spring Rain Action systematically collects clinical physician innovation ideas — unmet clinical needs, device design improvements, new clinical applications — and connects them with medical device R&D pipelines.

The mechanism: NMPA channels clinical physician input into a structured process that matches innovation ideas with manufacturers and research institutions, creating a full-chain coordination pathway from clinical need identification through R&D to clinical trial to registration. For foreign companies assessing China's innovation ecosystem, Spring Rain Action signals NMPA's active role in shaping which device categories receive the most regulatory development resources in coming years.

What This Means for Foreign Medical Device Manufacturers

The three-healthcare coordination framework creates a fundamentally different competitive environment from even five years ago:

• Registration alone is no longer enough for market access. A registered device needs a UDI, an insurance code, and hospital formulary inclusion to generate volume. These three steps each require separate administrative work — and each is now accelerating through the digital integration the framework is building.
• Innovative products have explicit policy protection from VBP — but only temporarily. The window of VBP-free market development is a strategic asset to be used aggressively for building clinical evidence and hospital relationships before the product category matures.
• The clinical urgent import pathway offers a legitimate early-access route for truly novel devices not yet registered in China. It generates real-world data while building clinical champions — the most valuable currency in China's hospital procurement decisions.
• UDI compliance is the baseline for system integration. Without UDI, devices are invisible to the insurance coding, VBP, and traceability systems that determine whether hospitals can efficiently procure and reimburse them.
• Priority review categories are explicitly named: medical robots, BCI devices, radiation therapy equipment, advanced imaging, innovative TCM diagnostic devices, and high-end implantables. Foreign manufacturers in these categories have a policy tailwind for faster NMPA review.

FAQ

三医协同政策下医疗器械监管新格局：UDI、集采与临床急需进口全解析（2025年）

中国医疗体制正经历数十年来最深刻的结构性调整。"三医协同"——医疗、医保、医药/医械协同改革——已从战略原则演变为具体操作指令。国务院办公厅印发的国办发〔2024〕53号文件，明确将具体任务分配至NMPA、国家医保局、国家卫健委、工信部及国家发改委。

对于在中国市场开展业务的医疗器械企业——尤其是境外企业——理解三医协同框架已成为必修课。它决定着创新产品进入市场的速度、能否纳入医保支付范围、UDI合规如何衔接采购与流通系统，以及集采中选后承担哪些质量义务。本文逐一解析各维度。

政策架构：国办发〔2024〕53号的核心任务

临床急需进口：未注册器械的合法进入路径

最具实操意义的新机制之一是2024年第97号公告确立的临床急需进口路径。该政策为具备资质的三级甲等医院开辟了一条合法渠道，可向NMPA申请临时进口已在境外获批但尚未在国内注册的二类、三类医疗器械。

适用范围与条件

• 仅适用于二类和三类医疗器械
• 产品须已在原产国获批上市
• 国内无同品种已注册产品（"同品种"认定标准与NMPA注册一致：基本原理、结构组成、主要原材料、生产工艺、性能要求、安全性评价、适用标准及预期用途基本等同）
• 属于临床急需：用于防治国内尚无有效替代手段的严重危及生命疾病
• 应纳入大型医用设备配置许可管理的设备不适用

申请医疗机构资质

• 须为三级甲等医院
• 具备相应疑难危重症诊治能力
• 有与申请器械预期用途相适应的高水平专业科室及资深专家团队
• 具备质量控制能力及不良事件监测与处置条件

申请与审批流程

紧急使用：突发公共卫生事件的独立通道

2023年第150号规定的紧急使用机制与临床急需进口有本质区别——仅适用于特别重大突发公共卫生事件。在国家卫健委和疾控局建议下，NMPA可授权特定产品在无完整注册情况下紧急部署使用。此路径非常规可用，专为真实公共卫生危机情境设计。

UDI：三医协同的数字化底座

在三医协同框架中，中国医疗器械唯一标识（UDI）系统不仅是追溯工具，更是实现生产、流通、临床使用全链条"一码联通"的信息基础设施，是打破NMPA、医保、医院、流通企业间信息孤岛的关键支撑。

结构与分步实施

中国UDI遵循IMDRF框架：每个器械携带产品标识（DI）与生产标识（PI），即UDI = DI + PI。分三批实施：

• 第一批：全部三类医疗器械（最高优先级，率先实施）
• 第二、三批：15,103种二类医疗器械产品

国家医疗器械唯一标识数据库已对外开放共享，生产企业、流通企业、医疗机构及医保系统均可访问，构成NMPA追溯、不良事件信号监测、采购核对和医院库存管理的统一数据来源。

UDI合规的超越追溯价值

• 医保编码关联：国家医保局正将UDI设备标识映射至医保产品编码。未在NMPA数据库中录入UDI的器械，无法被医保报销和国家采购招标系统高效处理。
• 集采资质：集采招标日益要求提供UDI信息用于产品入围及中选后质量追踪；NMPA利用UDI关联的不良事件数据对中选产品实施监控。
• 医院系统集成：主要医院信息系统（HIS）和手术器械追踪系统正整合UDI扫描功能，无UDI条码的器械将在医院采购和库存管理中面临摩擦。
• 召回效率：UDI追溯支持精准到批次级别的定向召回，而非大范围的产品级撤市，对企业商业利益和患者安全均有重要意义。

医保编码：解决"同名异物、异物同名"痼疾

长期以来，NMPA产品命名规范与国家医保局编码命名体系之间的不一致是中国医疗器械生态的慢性顽疾——同类产品名称各异，不同产品却同名，导致精准医保识别、采购匹配和费用管控极为困难。

三医协同框架通过系统性的医疗器械通用名称与医保通用名映射关系研究直接攻克这一问题：目标是使器械在获得NMPA注册证号和UDI后，能精准匹配至医保编码，实现准确报销归类、集采入围评估和医院目录管理。

医疗器械医保编码结构（医用成像设备示例）

拟议中的医保医用成像设备编码为13位结构：2位大写字母前缀"CS"（医用设备标识码）+ 6位分类码（前2位功能类别、中间2位技术原理、后2位用途/品名）+ 5位企业码（依据NMPA注册证为企业赋予的唯一流水码）。

这一编码架构旨在实现NMPA产品名称、UDI设备标识与医保编码之间的"三码映射"——这是三医协同在技术层面可行落地的核心前提。

集采：NMPA的质量监管角色

国家集采已覆盖冠脉支架、骨科（关节、脊柱、创伤）、人工晶体及血管介入导管等器械品类，价格大幅压缩。NMPA在集采中的定位是中选产品质量保障，而非价格谈判。

NMPA集采六大监管任务

1. 全面落实中选企业主体责任
2. 切实加强对中选企业的监督检查
3. 扎实做好流通使用环节监督检查
4. 认真开展中选品种质量抽检
5. 持续加强不良事件监测
6. 严肃查处违法违规行为

上述任务的制度化起点是NMPA领导层专程出席的冠脉支架集采质量安全会议——价格压缩背景下，产品质量受到最高级别的政治关注。

集采与创新器械：受保护的市场空间

三医协同政策明确承认集采价格压缩与激励器械创新之间的张力，并给出清晰的解决方案：临床使用尚未成熟、使用量暂难预估的创新器械，明确排除在强制集采范围之外。国家医保局政策在集采之外专门保留一定市场，为新批准创新器械提供构建临床证据、拓展医院关系的发展空间——然后才可能面临未来采购周期中的竞争。这一保护期是境外创新器械企业市场进入策略的核心考量。

新注册器械医保快速赋码

NMPA与医保局已建立赋码快速通道：已取得NMPA注册证的企业，可直接向国家医保局"医疗保障信息业务编码标准数据库动态维护"窗口提交注册证、产品说明书、产品实物照片等材料，NMPA承诺优先加快新注册器械的赋码进度。

LDT试点：院内创新与监管合规的交汇

LDT（实验室自建检测）试点制度——基于2021年《条例》第五十三条——处于三医协同框架对临床创新支持与监管现代化承诺的交汇点。试点允许符合条件的医疗机构在执业医师指导下自行研制IVD产品院内使用，无需单独NMPA注册。

政策逻辑：中国顶尖临床研究机构有能力开发出满足真实未满足临床需求的新型诊断检测——尤其是罕见病和特殊肿瘤领域——其速度可能快于商业化注册路径。LDT框架将这种临床创新纳入监管结构，而非放任院内自建检测无序增长。

春雨行动：临床到产业的创新转化通道

"春雨行动"是NMPA主导的主动性举措，为三医协同框架增添了前瞻维度。NMPA系统收集临床医生的创新创意——未满足的临床需求、器械设计改进建议、新型临床应用——并与医疗器械研发管线精准对接，构建从临床需求识别、研发立项到临床试验、注册上市的全链条协同通道。对于评估中国创新生态的境外企业而言，春雨行动预示着NMPA未来几年将向哪些器械品类集中投入监管开发资源。

对境外医疗器械企业的战略启示

• 注册证不再等同于市场准入。已注册器械还需完成UDI备案、医保编码赋码和医院目录纳入，才能真正产生销量。三医协同正在加速这三步的数字化整合。
• 创新产品有明确的集采豁免政策保护——但这是有限时间窗口。在集采竞争到来之前，这段受保护的市场发展期是企业积累临床证据和构建医院关系的战略资产。
• 临床急需进口路径是真正创新器械的合法早期进入通道，同时积累中国患者真实世界数据——这是中国医院采购决策中最有价值的"通货"。
• UDI合规是系统整合的入场券。没有UDI，器械对医保编码、集采和追溯系统均不可见，医院难以高效采购和报销。
• 优先审评品类已明确点名：医用机器人、脑机接口、放射治疗设备、高端影像、创新中医诊疗装备、高端植介入类器械。处于这些领域的境外企业享有加快NMPA审评的政策顺风。

常见问题